AllSci News
Prelude Therapeutics Launches Phase 1 Trial of JAK2 Inhibitor PRT12396 in Myeloproliferative Neoplasms
Prelude Therapeutics Incorporated (Nasdaq: PRLD) has registered a Phase 1 clinical trial for PRT12396, a first-in-class, oral, allosteric inhibitor that...
Immunocore's IMC-S118AI Enters Phase 1 Trial as First-in-Class PD-1 Agonist for Type 1 Diabetes
Immunocore Holdings plc has registered a Phase 1 first-in-human clinical trial (NCT07493122) for IMC-S118AI, a bispecific soluble TCR–PD-1 agonist fusion...
Astellas terminates first-in-human Phase I trial of ASP5502 in Sjögren's syndrome
Astellas Pharma (Japan) has terminated its Phase I clinical trial of ASP5502, an oral small-molecule STING (Stimulator of Interferon Genes) inhibitor, in...
JAX-NYSCF Collaborative and GSS plc 5-Year Strategic Partnership in Neurodegenerative Disease Research
The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) and GSK plc (LSE: GSK) have entered a five-year strategic research...
Moonlight Bio Launches Phase 1 First-in-Human Trial of ML261 CAR T Therapy for SCLC
Moonlight Bio, Inc., a Seattle-based cell therapy company founded in 2023, has registered a Phase 1 first-in-human clinical trial (NCT07488923) of ML261, an...
Basilea's BAL2420 enters the clinic as first-in-class LptA inhibitor targeting Gram-negative resistance
Basilea Pharmaceutica, the Swiss commercial-stage anti-infectives company, has dosed the first healthy volunteer in a phase 1 study of the BAL2420...
Xenon Pharmaceuticals' azetukalner achieves positive phase 3 results in focal onset seizures
Vancouver and Boston-based Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, a KV7 potassium channel...
Sanofi licenses KT501 tri-specific T-cell engager from Kali Therapeutics in USD 1.23b deal
Sanofi has licensed exclusive worldwide rights to KT501, a tri-specific T-cell engager developed by Kali Therapeutics, for the treatment of B cell-mediated...
China's NMPA grants priority review to Gyre Therapeutics' Hydronidone for CHB-induced liver fibrosis
Gyre Therapeutics has announced that China's National Medical Products Administration (NMPA), through its Center for Drug Evaluation (CDE), has granted...
City Therapeutics Launches Phase 1 Trial of CITY-FXI siRNA for Inherited Thrombophilia
City Therapeutics, Inc. has begun dosing participants in a Phase 1 clinical trial of CITY-FXI, a small interfering RNA (siRNA) that targets Factor XI (FXI)...
Rallybio's RLYB116 achieves complete C5 blockade in Phase 1 for platelet transfusion refractoriness
Rallybio Corporation announced positive results from a Phase I confirmatory pharmacokinetic/pharmacodynamic study of RLYB116, a subcutaneously administered...
Whitehawk Therapeutics Launches Phase 1 First-in-Human Trial of MUC16-Directed ADC HWK-016 in Ovarian Cancer
Whitehawk Therapeutics has begun recruiting patients into a Phase 1 first-in-human clinical trial (NCT07470853) of HWK-016, a MUC16-directed antibody-drug...
Merck Acquires Terns Pharmaceuticals for USD 6.7b to Boost Hematology Pipeline With CML Drug
Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage oncology company, for USD 53.00...
Mirador Therapeutics Launches Phase 1 Trial of MT-251 Bispecific Antibody Targeting TL1A and IL-23
Mirador Therapeutics has initiated dosing in a Phase 1 MT-251 clinical trial evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of...
Apertura Gene Therapy and Viralgen partner to manufacture blood-brain barrier-crossing AAV capsid for CNS gene therapy
Apertura Gene Therapy and Viralgen, a contract development and manufacturing organization based in San Sebastián, Spain, have entered a manufacturing...
The AllSci Brief
Systematic R&D and deal news. Daily.